Long-term suppression of glucagon signaling is potentially an effective therapy for heart failure with different etiologies independent of metabolic disorders.
SUMMARY
Mice were treated with a fully human monoclonal glucagon receptor antagonistic antibody REMD2.59 following myocardial infarction or pressure overload. REMD2.59 treatment blunted cardiac hypertrophy and fibrotic remodeling, and attenuated contractile dysfunction at 4 weeks after myocardial infarction. In addition, REMD2.59 treatment at the onset of pressure overload significantly suppressed cardiac hypertrophy and chamber dilation with marked preservation of cardiac systolic and diastolic function. Initiation of REMD2.59 treatment 2 weeks after pressure overload significantly blunted the progression of cardiac pathology. These results provide the first in vivo proof-of-concept evidence that glucagon receptor antagonism is a potentially efficacious therapy to ameliorate both onset and progression of heart failure. Glucagon (GLC) is a peptide hormone produced by pancreatic a-cells (2) (3) (4) (5) (6) . As a major catabolic hormone, GLC stimulates glucose production from glycogen in liver and promotes gluconeogenesis while it inhibits glycolysis and glycogen synthesis (4) .
It increases blood glucose and energy expenditure as part of the energy mobilization process in response to hypoglycemia and other bioenergetic stress. Consequently, GLC serves as a counterbalancing hormone with insulin to regulate glucose homeostasis depending on nutrient conditions and available energy sources (7) . The GLC receptor (GCGR) is a member of the G protein-coupled receptor family (3, 6, 8, 9) .
The canonical function of GCGR elicited by GLC is mediated by G protein-coupled protein kinase A activation; however, tissue-specific function of GCGR has been implicated in different cellular processes (2, 3, 10) . Elevated GLC is observed in chronic hyperglycemia associated with type 1 or type 2 diabetes (11) (12) (13) . Overactivated GLC signaling may contribute to disease progression of diabetes by enhancing glucose production and aggravating systemic hyperglycemia, as well as impairing insulin signaling. Therefore, GCGR inhibition, using either small molecules or antagonistic antibodies, is potentially efficacious to treat diabetes as demonstrated in both preclinical studies as well as several recent clinical trials (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) . However, much of the previous studies on GLC signaling are in the liver and brain, involving glucose metabolic regulation (2, 3, 22) . Its specific and cell-autonomous role in cardiac tissue has just begun to be appreciated.
Other than glucose regulation in liver, GCGR is also widely expressed in multiple other tissues, including the heart (3, 15, 18, (23) (24) (25) (26) (27) (28) . In a recent study by Ali et al. (29) , GLC stimulation was shown to promote ischemia injury in mouse heart while cardiomyocyte specific GCGR inactivation protected the heart from pathological remodeling following myocardial infarction.
This study highlights the potential cardiomyocyte cell-autonomous effect of GCGR overactivation in cardiac pathological remodeling, and GCGR antagonism as a potential therapy for heart failure. REMD-477 is a fully human anti-GCGR antibody that competitively blocks GLC binding to the GCGR with 30-pM binding affinity, and can effectively inhibit the receptor activity at low nanomolar concentrations in cell-based functional assays (14, 17, 20) . Compared with small-molecule approaches (30) , antibody-based GCGR antagonism such as REMD-477 is a competitive antagonist and does not have deleterious effects on serum lipid profiles (11, 12, 19, 21, 31 
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has been shown to be safe in a phase I study (NCT02715193) and is being tested in 2 phase II clinical studies (NCT03117998 and NCT02455011 for type 1 and type 2 diabetes, respectively). In short, anti-GCGR antibody offers a novel tool to effectively and specifically inhibit GCGR with proven record of clinical safety and efficacy at molecular and metabolic levels.
Functionally identical as REMD-477, REMD2.59 is a surrogate human antibody specifically generated for preclinical studies in rodents (32) . In a recent study, weekly treatment with REMD2.59 is shown to reverse diabetes in ob/ob mice and improves cardiac function associated with diabetic cardiomyopathy (32) .
Although this study supports the cardioprotective effect of GCGR antagonism, it is not clear whether the beneficial effect is a direct consequence of cardioprotection on cardiomyocyte or an indirect result of improved global glucose homeostasis and insulin signaling. In the current study, we employed 2 mechanistically divergent and diabetes-independent murine disease models for heart failure, myocardial infarction, and pressure overload, to test whether the cardioprotection by the GCGR antibody is the primary effect of the receptor inhibition. Based on morphological, functional, and molecular parameters, treatment with GCGR antibody REMD2.59 significantly ameliorated the development of heart failure, by attenuating pathological remodeling and cardiac hypertrophy while preventing functional deterioration and pathological gene expression. These novel and exciting observations implicate a potential role of GLC-mediated signaling in heart failure via a cardiomyocyte cell-autonomous mechanism. It raises the prospect of targeting GCGR as potential therapy to treat common forms of heart failure independent of the confounding status of global glucose metabolic disorders.
METHODS
ANIMALS. C57BL/6 male mice (Jackson Laboratory, Bar Harbor, Maine) were used in this study, and all mice were housed in groups of 4 to 5 mice per cage in a room maintained at 23 AE 1 C and 55 AE 5% humidity with a 12-h light-dark cycle and given ad libitum access to food and water. .
Gao et al. 100 to 150 cells/heart were analyzed based on wheat germ agglutinin staining. Two methods were used to assess the size of the infarcted heart. Infarct area was calculated as a percentage of infarcted ventricular area to total ventricular area using the front and back sides of the heart photos. Infarct size was measured as a percentage of infarcted ventricular wall length to total ventricular wall length using cardiac sections.
The observer was blinded to the origin of the cardiac sections.
TUNEL assay was performed with the In-Situ
Apoptosis Detection Kit (Thermo Fisher Scientific, Waltham, Massachusetts). Briefly, hearts were fixed by perfusion with 10% formalin solution, embedded in paraffin, and sectioned at 6 mm. One middle longitudinal section per heart was taken for TUNEL staining.
Proteinase K (20 mg/ml) was added to each slide. with CFX-96 Real-time PCR Detection System (Bio-Rad Laboratories) with primers as described in It is noted that the mice from hemodynamic studies had average heart rates (378 AE 94 beats/min, 363 AE 71 beats/min, 431 AE 114 beats/min for vehicle-, REMD-, and GLC-treated groups, respectively). In contrast, the average heart rates of mice for the echocardiograph studies were 626 AE 18 beats/min, 657 AE 9 beats/min, and 662 AE 7 beats/min for the same groups, respectively. Therefore, the hemodynamic measurements were measured under a significantly depressed state, likely due to anesthesia. Nevertheless, there were no differences in heart rates among the 3 experiment groups in either measurements, suggesting that the differences observed in the hemodynamic or echocardiographic parameters were not the results of differential degrees of anesthesia levels.
GCGR INHIBITION ON PRESSURE OVERLOAD-INDUCED
CARDIAC HYPERTROPHY. To demonstrate the applicability of GCGR antagonism therapy to heart failure with different etiologies, we investigated the impact of REMD2.59 on pressure overload induced cardiac hypertrophy, dysfunction, and remodeling. Pressure overload was induced by TAC as described previously (33,34) in C57BL/6 male mice 8 to 10 weeks of age PBS ¼ phosphate-buffered saline; s.c. ¼ subcutaneous.
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GR Antagonism Ameliorates Progression of HF
A P R I L 2 0 1 9 : 1 6 1 -7 2 along with pulmonary congestion ( Figure 6B ). Figure 6B ). All these evidences suggest that GCGR antagonism exerts significant protection against pressure overload induced cardiac dysfunction and blunts progression of heart failure.
GCGR ANTAGONISM ON PATHOLOGICAL REMOD-
ELING IN THE PRESSURE-OVERLOADED HEART. As a common feature of cardiac remodeling, chronic Figure 1 .
DISCUSSION
In this report, the therapeutic effect of a GCGR antagonistic antibody REMD2.59 was tested in 2 mechanistically divergent disease models of heart failure without confounding defects in global Gao et al.
GR Antagonism Ameliorates Progression of HF
A P R I L 2 0 1 9 : 1 6 1 -7 2 inhibiting glycolysis (7, 35) . In addition to its predominant expression in liver, GCGR is also expressed at modest to low levels in the kidney, heart, pancreas, and many other tissues (3, 8, 36) . Although G proteincoupled canonical signaling for GLC is well established in hepatocytes, other mechanisms involving intracellular calcium regulation have also been reported in nonhepatocytes including cardiomyocytes (3, 10, 28, 36) . In this report, we investigated GCGR in- It is important to note that when REMD2.59 was applied 2 weeks after the onset of pressure overload, Gao et al.
GCGR antagonism no longer had any significant impact on cardiac hypertrophy, but still preserved the residual functions of the heart (Figures 6 and 7) . This is consistent with previously reported observation that cardiomyocyte hypertrophy is established rather early in response to pressure overload while contractile dysfunction and fibrotic remodeling will continue to manifest (33) . Our results highlight the potential limitation in the therapeutic window for heart failure. Nevertheless, REMD treatment can halt the further progression of heart failure and remodeling despite the limitation that GCGR antagonism may not be sufficient to reverse established cardiac hypertrophy and to fully restore contractile function.
It is clear that more studies will be needed to fully establish the therapeutic efficacy of GCGR antagonism. Clinically relevant large animal models with established heart failure will be needed, and longerterm treatment and better outcome-based measurements (e.g., death and exercise tolerance) will be required.
Extensive pharmacological and structural analysis shows GCGR antibody REMD-477 competitively blocks GLC binding to the GCGR with 30-pM binding affinity, and can fully inhibit the receptor activity at low nanomolar concentrations in cells (14, 17, 20) .
Functionally identical to REMD-477, REMD2.59 is a surrogate human antibody specifically generated for chronical preclinical studies in rodents and primates.
Unlike previous small-molecule approaches (30), REMD-477 does not have deleterious effects on serum lipid profiles (11, 12, 19, 21, 31) unclear if these therapies will be efficacious for common forms of heart failure without the confounding metabolic disorders. Our current study in 2
heart failure disease models free from systemic metabolic disorders further supports that GCGR inhibition may be repurposed as an effective therapy for common forms of heart failure.
ACKNOWLEDGMENT The authors wish to thank Ms. Haiying Pu for excellent technical assistance. ischemic injury in the heart, and prevents pathological remodeling and heart failure induced by mechanic overload in nonobese and nondiabetic mice.
TRANSLATIONAL OUTLOOK: Systemic treatment of GCGR antagonist can be considered as a potential therapy for heart failure with different etiologies without concurrent metabolic disorders.
